Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 39 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

54%

21 trials in Phase 3/4

Results Transparency

21%

5 of 24 completed with results

Key Signals

5 with results100% success

Data Visualizations

Phase Distribution

34Total
Not Applicable (2)
P 1 (7)
P 2 (4)
P 3 (13)
P 4 (8)

Trial Status

Completed24
Unknown4
Active Not Recruiting3
Withdrawn3
Recruiting3
Not Yet Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 24 completed trials

Clinical Trials (39)

Showing 20 of 20 trials
NCT05745883Phase 1Completed

Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia

NCT06520826Phase 3Active Not RecruitingPrimary

Vafseo Outcomes In-Center Experience

NCT06901505Phase 3Active Not RecruitingPrimary

To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis

NCT05082571Phase 3WithdrawnPrimary

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease

NCT05082584Phase 3WithdrawnPrimary

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents

NCT04543812Phase 3CompletedPrimary

PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD

NCT05544513Phase 2Active Not Recruiting

Oral Iron Supplementation for Patients With Chronic Kidney Disease

NCT04036253Phase 3CompletedPrimary

Study of HEMAX PFS Versus EPREX/ ERYPO® in Predialysis Chronic Kidney Disease

NCT05515367Phase 4Recruiting

A Post Marketing Surveillance to Evaluate the Safety of Desidustat for the Treatment of Anemia in Subjects With Chronic Kidney Disease (CKD).(Real World Evidence Study)

NCT06352138Phase 3Not Yet RecruitingPrimary

Comparative Study of Two Recombinant Human Erythropoietin Products in Chronic Kidney Disease Patients

NCT06556134Phase 4CompletedPrimary

Oral Liposomal Iron Versus Injectable Iron Sucrose for Anemia Treatment in Non-Dialysis Chronic Kidney Disease Patients

NCT06466785Phase 3RecruitingPrimary

A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis

NCT06463236Not ApplicableRecruitingPrimary

Clinical Validation of the Management Process for Renal Anemia in Maintenance Hemodialysis Patients

NCT05698420Completed

Investigation of the Effects of Medium Cut-off Dialyzers Versus High-Flux Dialyzers on Clinical and Laboratory Parameters of Prevalent Hemodialysis Patients

NCT04655027Phase 4CompletedPrimary

A Study to Investigate the Effect of Roxadustat Versus Recombinant Human Erythropoietin (rHuEPO) on Oral Iron Absorption in Chinese Patients With Anemia of Chronic Kidney Disease (CKD)

NCT05900635Phase 4UnknownPrimary

Effect of Adding Lactoferrin on Oral Iron on Anemia in Chronic Kidney Disease Patients

NCT05699109CompletedPrimary

Erythropoiesis Stimulating Agents for Anemia Management in Egyptian Hemodialysis Patients

NCT04667533Phase 1CompletedPrimary

Desidustat in the Treatment of Chemotherapy Induced Anemia

NCT04959578Phase 4CompletedPrimary

Comparison of Darbepoetin Alpha and Recombinant Human Erythropoietin for Treatment of Anemia in Children With Chronic Kidney Disease

NCT03633656Phase 4Completed

Iron Dosing Pilot Study Using Model Predictive Control

Scroll to load more

Research Network

Activity Timeline